UniQure: A Dark Horse in the Gene Therapy Field
Research - We see uniQure (QURE) as a dark horse in gene therapy, in-part because of numerous catalysts in 2015 that will put fresh eyes on this European company.
Read nowAuthor Archives: Zack Fink
“New” Tekmira Emerges as HBV Frontrunner
Research - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read now
Here’s What bluebird bio Investors Should Know about Sickle Cell Disease
Research - By Zack Fink and guest contributor Dan Marks Bluebird bio (BLUE) will release data from the first Sickle Cell Disease patient treated with its LentiGlobin gene therapy … Continue Reading
Read now
Kite Pharma Inks Deal with Amgen in Move Towards ‘Platform’ Model
Insights - Shortly before the bell on Monday morning, Kite Pharma (KITE) announced an immunotherapy collaboration and licensing agreement with one of biotech’s juggernauts, Amgen (AMGN), to advance … Continue Reading
Read now
Checkpoint Inhibitors: What are They and One Compelling Small-Cap Player
Research - Immune checkpoint regulators are again making headlines, this time at the American Society of Hematology, where they are demonstrating exciting early efficacy in hematological malignancies. … Continue Reading
Read nowOn Bluebird Bio After a Glimpse at Preliminary Lentiglobin Data
Research - Last week, preliminary data for bluebird bio (BLUE)’s Lentiglobin were released as part of the abstract dump for ASH in December (we wrote at length about this, here). Bluebird … Continue Reading
Read now
ASH 2014 Abstracts are About to Hit: Here are Some of the Names to Follow
Research - The American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. This, and the … Continue Reading
Read now